Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed

benzinga.com/general/health-care/25/05/45245367/novo-nordisks-weight-loss-blockbuster-faces-setback-from-us-compounding-surge-forecast-trimme

Novo Nordisk A/S (NYSE:NVO) slashed its 2025 sales forecast Wednesday, citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments in the U.S. market due to competition from compounded versions of the drugs.
What Happened: The Danish pharmaceutical…

This story appeared on benzinga.com, 2025-05-07 07:36:19.
The Entire Business World on a Single Page. Free to Use →